HAEHealthcare · Medical DevicesThe 11 Wall Street analysts covering Haemonetics Corp. hold a median 12-month price target of $124 — +2.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 14 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Haemonetics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (97): The share count has been shrinking and the company is not leaning on new borrowing.
Growth (47): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (21): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on HAE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +2.4% from it.
Of the 20 most recent actions, 11 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Oct 2026 | Barrington Research | Maintains | Outperform | $118 → $140 |
| 9 Oct 2026 | Mizuho | Maintains | Outperform | $95 → $140 |
| 8 Oct 2026 | BTIG | Maintains | Buy | $110 → $130 |
| 17 Sept 2026 | Citigroup | Upgrade | Buy | — |
| 17 Sept 2026 | Citigroup | Upgrade | Buy | $92 → $123 |
| 3 Sept 2026 | Raymond James | Maintains | Outperform | $105 → $125 |
| 3 Sept 2026 | Raymond James | Maintains | Outperform | — |
| 21 Aug 2026 | Baird | Maintains | Outperform | $96 → $119 |
| 21 Aug 2026 | Baird | Maintains | Outperform | — |
| 19 Aug 2026 | Barrington Research | Maintains | Outperform | — |
| 19 Aug 2026 | Barrington Research | Maintains | Outperform | $95 → $118 |
| 18 Aug 2026 | BTIG | Maintains | Buy | $96 → $110 |
| 18 Aug 2026 | BTIG | Maintains | Buy | — |
| 7 Aug 2026 | Citigroup | Maintains | Neutral | — |
| 7 Aug 2026 | Citigroup | Maintains | Neutral | $79 → $92 |
| 7 Aug 2026 | JP Morgan | Maintains | Neutral | — |
| 7 Aug 2026 | JP Morgan | Maintains | Neutral | $62 → $86 |
| 6 Aug 2026 | BTIG | Maintains | Buy | $84 → $96 |
| 6 Aug 2026 | BTIG | Maintains | Buy | — |
| 15 July 2026 | Mizuho | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HAE appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Haemonetics Corp. returned +143.4% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 12% of US stocks
Cheaper than 29% of US stocks
Cheaper than 14% of US stocks
Cheaper than 17% of US stocks
Higher than 40% of US stocks
Higher than 33% of US stocks
Higher than 73% of US stocks
Higher than 76% of US stocks
Higher than 65% of US stocks
Higher than 66% of US stocks
Higher than 84% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Haemonetics Corp. has a market value of $5.6B and an enterprise value of $6.5B.
Revenue in the twelve months to 30 June 2026: $1.4B. The latest quarter grew 5.6% year on year.
Net income over the same four quarters: $96.3M, a 7.1% net margin.
Diluted earnings per share, trailing twelve months: $2.04.
Free cash flow in the twelve months to 30 June 2026: $291.2M, after $36.9M of capital spending.
Trailing P/E: 59.0×; forward P/E: 21.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Haemonetics Corp. employs 3,009 people — $449K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Haemonetics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research’s headline describes Haemonetics (HAE) as a top momentum stock for the long term. The excerpt points readers to Zacks Style Scores as a way to identify stocks, but provides no further HAE-specific details.
Why it matters — HAE watchers may note the favorable momentum framing, while the excerpt does not explain the basis for the characterization.
Haemonetics was a big mover in the latest session, with higher-than-average trading volume. The excerpt says earnings estimate revisions may not support further near-term gains.
Why it matters — HAE watchers may note the recent trading activity alongside the potentially less supportive earnings estimate revision trend.
Haemonetics shares rose more than 13% to $115.20 on Thursday after CSL said it expects to complete the rollout of Haemonetics’ NexSys PCS devices with Persona PLUS technology and related disposables across its US plasma collection centers by the end of 2027.
Why it matters — The announced timetable provides Haemonetics watchers with an update on the planned deployment of its plasma collection devices at CSL’s US centers.
CSL Plasma plans to use Haemonetics’ plasma collection equipment across all of its existing U.S. centers, expanding the scope of an earlier supply agreement.
Why it matters — The expanded agreement could broaden the reach of Haemonetics’ equipment within CSL Plasma’s U.S. network.
Zacks Investment Research published an article comparing Phibro Animal Health (PAHC) and Haemonetics (HAE) as value opportunities for investors in Medical - Products stocks. The piece asks which of the two companies presents a better value option at this time.
Why it matters — The article positions Haemonetics in a comparative value assessment against a peer, which may inform how investors evaluate its valuation metrics.
The 11 Wall Street analysts covering Haemonetics Corp. have a median 12-month price target of $124, with estimates ranging from $86 to $140. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Haemonetics Corp., 9 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Haemonetics Corp. 99 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Haemonetics Corp. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (97 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +2.4% from the last close, and Ticker Nerd's factor model ranks Haemonetics Corp. 99 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Haemonetics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HAE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $86 to $140 over the next 12 months.
Haemonetics Corp. returned +143.4% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Haemonetics Corporation is a medical technology company that develops products and services for blood and plasma collection, hospital transfusion management, and selected interventional procedures. Its Plasma segment provides automated collection systems, donor management software, and related disposables that support plasma centers and improve operational efficiency.
The most recent item we track (Zacks Investment Research, 13 Oct 2026): "Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term". Zacks Investment Research’s headline describes Haemonetics (HAE) as a top momentum stock for the long term. The excerpt points readers to Zacks Style Scores as a way to identify stocks, but provides no further HAE-specific details.
Haemonetics Corporation is a medical technology company that develops products and services for blood and plasma collection, hospital transfusion management, and selected interventional procedures. Its Plasma segment provides automated collection systems, donor management software, and related disposables that support plasma centers and improve operational efficiency. The Blood Center segment offers apheresis and whole blood collection solutions used to collect and process blood components for transfusion. The Hospital segment includes blood management technologies, hemostasis management systems, surgical blood salvage products, vascular closure devices, and sensor-guided tools designed to support clinical decision-making and procedural performance. Headquartered in Boston, Massachusetts, Haemonetics serves healthcare providers and collection centers across global markets.
CEO Mr. Christopher A. Simon · 3,009 employees · United States · https://www.haemonetics.com
